Wanted, dead or alive: New viral vaccines

Antiviral Research

Volumn 84, Issue 2, 2009, Pages 119-130

  Amanna, Ian J ^a   Slifka, Mark K ^b  

^a Najít Technologies Inc   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Antibody; B cell; Immunological memory; T cell; Vaccine; Virus

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HERPES ZOSTER IMMUNOGLOBULIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN; INACTIVATED VIRUS VACCINE; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; ORAL POLIOMYELITIS VACCINE; PLACEBO; PNEUMOCOCCUS VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; ROTAVIRUS VACCINE; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VACCINIA ANTIBODY; VIRUS VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE; ZHEPU;

AGAMMAGLOBULINEMIA; ANTIBODY RESPONSE; BRONCHIOLITIS; CELLULAR IMMUNITY; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; HEPATITIS A; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INFECTION PREVENTION; LOW DRUG DOSE; MEASLES; MONKEYPOX; NONHUMAN; PASSIVE IMMUNIZATION; PNEUMONIA; POLIOMYELITIS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SECONDARY INFECTION; SEVERE COMBINED IMMUNODEFICIENCY; SINGLE DRUG DOSE; SMALLPOX; VACCINE FAILURE; VACCINIA; VACCINIA GANGRENOSA; VIRUS INFECTION; YELLOW FEVER;

ANIMALS; ANTIBODIES, VIRAL; DRUG DESIGN; HUMANS; IMMUNOLOGIC MEMORY; T-LYMPHOCYTES; VACCINES, ATTENUATED; VIRAL VACCINES; VIRUS DISEASES; VIRUS REPLICATION; VIRUSES;

EID: 70349472911     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.08.008     Document Type: Review

References (128)

1. Alexander L.N., Seward J.F., Santibanez T.A., Pallansch M.A., Kew O.M., Prevots D.R., Strebel P.M., Cono J., Wharton M., Orenstein W.A., and Sutter R.W. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 292 (2004) 1696-1701
2. Amanna I., and Slifka M.K. Public fear of vaccination: separating fact from fiction. Viral Immunol. 18 (2005) 307-315
3. Amanna I.J., Carlson N.E., and Slifka M.K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357 (2007) 1903-1915
4. American Academy of Pediatrics. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 112 (2003) 1442-1446
5. Annunziato D., Kaplan M.H., Hall W.W., Ichinose H., Lin J.H., Balsam D., and Paladino V.S. Atypical measles syndrome: pathologic and serologic findings. Pediatrics 70 (1982) 203-209
6. Baba T.W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., Cavacini L.A., Posner M.R., Katinger H., Stiegler G., Bernacky B.J., Rizvi T.A., Schmidt R., Hill L.R., Keeling M.E., Lu Y., Wright J.E., Chou T.C., and Ruprecht R.M. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6 (2000) 200-206
7. Barrett A.D., Monath T.P., Barban V., Niedrig M., and Teuwen D.E. 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005. Vaccine 25 (2007) 2758-2765
8. Belyakov I.M., Earl P., Dzutsev A., Kuznetsov V.A., Lemon M., Wyatt L.S., Snyder J.T., Ahlers J.D., Franchini G., Moss B., and Berzofsky J.A. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 9458-9463
9. Bortin M.M., and Rimm A.A. Severe combined immunodeficiency disease. Characterization of the disease and results of transplantation. JAMA 238 (1977) 591-600
10. Bottiger M. A study of the sero-immunity that has protected the Swedish population against poliomyelitis for 25 years. Scand. J. Infect. Dis. 19 (1987) 595-601
11. Bottiger M. Polio immunity to killed vaccine: an 18-year follow-up. Vaccine 8 (1990) 443-445
12. Bottiger M., Gustavsson O., and Svensson A. Immunity to tetanus, diphtheria and poliomyelitis in the adult population of Sweden in 1991. Int. J. Epidemiol. 27 (1998) 916-925
13. Bottiger M., Zetterberg B., and Salenstedt C.R. Seroimmunity to poliomyelitis in Sweden after the use of inactivated poliovirus vaccine for 10 years. Bull. World Health Organ. 46 (1972) 141-149
14. Boulter E.A., Zwartouw H.T., Titmuss D.H., and Maber H.B. The nature of the immune state produced by inactivated vaccinia virus in rabbits. Am. J. Epidemiol. 94 (1971) 612-620
15. Brown F. Review of accidents caused by incomplete inactivation of viruses. Dev. Biol. Stand. 81 (1993) 103-107
16. Bruton O.C. Agammaglobulinemia. Pediatrics 9 (1952) 722-728
17. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., Gilbert P.B., Lama J.R., Marmor M., Del Rio C., McElrath M.J., Casimiro D.R., Gottesdiener K.M., Chodakewitz J.A., Corey L., and Robertson M.N. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372 (2008) 1881-1893
18. Buckley R.H., Schiff R.I., Schiff S.E., Markert M.L., Williams L.W., Harville T.O., Roberts J.L., and Puck J.M. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J. Pediatr. 130 (1997) 378-387
19. Casadevall A. Antibody-based therapies for emerging infectious diseases. Emerg. Infect. Dis. 2 (1996) 200-208
20. Casadevall A. Passive antibody therapies: progress and continuing challenges. Clin. Immunol. 93 (1999) 5-15
21. Casadevall A., and Scharff M.D. Return to the past: the case for antibody-based therapies in infectious diseases. Clin. Infect. Dis. 21 (1995) 150-161
22. CDC, 2005a. Epidemiology and prevention of vaccine-preventable diseases course textbook. National Immunization Program, Atlanta, GA.
23. CDC, 2005b. Health Information for International Travel 2005-2006. US Department of Health and Human Services, Public Health Service, Atlanta.
24. CDC, 2007. Update on vaccine-derived polioviruses-worldwide, January 2006-August 2007. MMWR Morb Mortal Wkly Rep 56, 996-1001.
25. CDC, 2009. Recommended immunization schedules for persons aged 0 through 18-United States, 2009. MMWR 57.
26. Chaves S.S., Gargiullo P., Zhang J.X., Civen R., Guris D., Mascola L., and Seward J.F. Loss of vaccine-induced immunity to varicella over time. N. Engl. J. Med. 356 (2007) 1121-1129
27. Clemens J.D., Sack D.A., Harris J.R., Chakraborty J., Khan M.R., Stanton B.F., Kay B.A., Khan M.U., Yunus M., Atkinson W., et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 2 (1986) 124-127
28. Clemens J.D., Sack D.A., Harris J.R., Van Loon F., Chakraborty J., Ahmed F., Rao M.R., Khan M.R., Yunus M., Huda N., et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 335 (1990) 270-273
29. Co M.D., Terajima M., Cruz J., Ennis F.A., and Rothman A.L. Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology 293 (2002) 151-163
30. Couzi G., and Kircher J.P. Immunotherapie de la Variole. Bulletin de l'Institut d'hygiene du Maroc 1 (1941) 59-68
31. Crotty S., Felgner P., Davies H., Glidewell J., Villarreal L., and Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol. 171 (2003) 4969-4973
32. Cutts, F.T. 1993. Measles, The Immunological Basis for Immunization Series. Module 7, World Health Organization Global Programme for Vaccines and Immunization, Geneva, Switzerland.
33. Cutts, F.T. 1996. Measles, The Immunological Basis for Immunization Series. Module 7, World Health Organization Global programme for Vaccines and Immunization, Geneva, Switzerland, pp. 20.
34. Dagan R., Greenberg D., and Weber F. Immunogenicity of an inactivated hepatitis A pediatric vaccine: three-year post-booster follow-up. Vaccine 23 (2005) 5144-5148
35. De Swart R.L., Kuiken T., Timmerman H.H., van Amerongen G., Van Den Hoogen B.G., Vos H.W., Neijens H.J., Andeweg A.C., and Osterhaus A.D. Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection. J. Virol. 76 (2002) 11561-11569
36. Delgado M.F., Coviello S., Monsalvo A.C., Melendi G.A., Hernandez J.Z., Batalle J.P., Diaz L., Trento A., Chang H.Y., Mitzner W., Ravetch J., Melero J.A., Irusta P.M., and Polack F.P. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15 (2009) 34-41
37. Doblas A., Domingo C., Bae H.G., Bohorquez C.L., de Ory F., Niedrig M., Mora D., Carrasco F.J., and Tenorio A. Yellow fever vaccine-associated viscerotropic disease and death in Spain. J. Clin. Virol. 36 (2006) 156-158
38. Dubois M.E., Yoshihara P., and Slifka M.K. Antibody-mediated protection against respiratory viral infection. Semin. Respir. Crit. Care Med. 26 (2005) 635-642
39. Edghill-Smith Y., Golding H., Manischewitz J., King L.R., Scott D., Bray M., Nalca A., Hooper J.W., Whitehouse C.A., Schmitz J.E., Reimann K.A., and Franchini G. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat. Med. 11 (2005) 740-747
40. Eibl M.M. History of immunoglobulin replacement. Immunol. Allergy Clin. North Am. 28 (2008) 737-764 viii
41. Endo A., Izumi H., Miyashita M., Taniguchi K., Okubo O., and Harada K. Current efficacy of postexposure prophylaxis against measles with immunoglobulin. J. Pediatr. 138 (2001) 926-928
42. Enria D.A., and Barrera Oro J.G. Junin virus vaccines. Curr. Top. Microbiol. Immunol. 263 (2002) 239-261
43. Enria D.A., Briggiler A.M., and Sanchez Z. Treatment of Argentine hemorrhagic fever. Antiviral Res. 78 (2008) 132-139
44. Fenner, F., Henderson, D.A., Arita, I., Jezek, Z., Ladnyi, I.D., 1988. Smallpox and its eradication, The pathogenesis, immunology, and pathology of smallpox and vaccinia, World Health Organization, Geneva, pp. 1469.
45. Fischer A. Severe combined immunodeficiencies (SCID). Clin. Exp. Immunol. 122 (2000) 143-149
46. Gerasimon G., and Lowry K. Rare case of fatal yellow fever vaccine-associated viscerotropic disease. South Med. J. 98 (2005) 653-656
47. Giurca A., Topciu V.L., Voiculescu D., Moldovan E., and Plavosin L. Investigations on allergic and serological reactions following inoculation of inactivated smallpox vaccines by cutaneous scarification. Virologie 27 (1976) 173-177
48. Good R.A., and Zak S.J. Disturbances in gamma globulin synthesis as experiments of nature. Pediatrics 18 (1956) 109-149
49. Gordon J.E., and Hughes T.P. A study of inactivated yellow fever virus as an immunizing agent. J. Immunol. 30 (1935) 221-234
50. Haigwood N.L., Montefiori D.C., Sutton W.F., McClure J., Watson A.J., Voss G., Hirsch V.M., Richardson B.A., Letvin N.L., Hu S.L., and Johnson P.R. Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J. Virol. 78 (2004) 5983-5995
51. Hammarlund E., Lewis M.W., Hansen S.G., Strelow L.I., Nelson J.A., Sexton G.J., Hanifin J.M., and Slifka M.K. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 9 (2003) 1131-1137
52. Hammitt L.L., Bulkow L., Hennessy T.W., Zanis C., Snowball M., Williams J.L., Bell B.P., and McMahon B.J. Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults. J. Infect. Dis. 198 (2008) 1776-1782
53. Hansen S.G., Vieville C., Whizin N., Coyne-Johnson L., Siess D.C., Drummond D.D., Legasse A.W., Axthelm M.K., Oswald K., Trubey C.M., Piatak Jr. M., Lifson J.D., Nelson J.A., Jarvis M.A., and Picker L.J. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 15 (2009) 293-299
54. Harrison L.H., Halsey N.A., McKee Jr. K.T., Peters C.J., Barrera Oro J.G., Briggiler A.M., Feuillade M.R., and Maiztegui J.I. Clinical case definitions for Argentine hemorrhagic fever. Clin. Infect. Dis. 28 (1999) 1091-1094
55. Hessell A.J., Poignard P., Hunter M., Hangartner L., Tehrani D.M., Bleeker W.K., Parren P.W., Marx P.A., and Burton D.R. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15 (2009) 951-954
56. Hindle E. A yellow fever vaccine. Br. Med. J. 1 (1928) 976-977
57. Itoh M., Okuno Y., and Hotta H. Comparative analysis of titers of antibody against measles virus in sera of vaccinated and naturally infected Japanese individuals of different age groups. J. Clin. Microbiol. 40 (2002) 1733-1738
58. Janeway C. Use of concentrated human serum g-globulin in the prevention and attenuation of measles. Bull. NY Acad. Med. 21 (1945) 202-222
59. Jenner E. An Inquiry into the Causes and Effects of the Variolae Vaccinae (1798), Sampson Low, London
60. Jenner E. Further Observations on the Variolae Vaccinae (1799), Sampson Low, London
61. Jenner E. A Continuation of Facts and Observations Relative to the Variolae Vaccinae, or Cowpox (1800), Sampson Low, London
62. Johnson P.R., Schnepp B.C., Zhang J., Connell M.J., Greene S.M., Yuste E., Desrosiers R.C., and Reed Clark K. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat. Med. 15 (2009) 901-906
63. Kaplan C. A non-infectious smallpox vaccine. Lancet 2 (1962) 1027-1028
64. Kaplan C., Mc C.D., and Vallet L. A note on the immunogenicity of ultra-violet irradiated vaccinia virus in man. J. Hyg. (Lond.) 60 (1962) 79-83
65. Keller M.A., and Stiehm E.R. Passive immunity in prevention and treatment of infectious diseases. Clin. Microbiol. Rev. 13 (2000) 602-614
66. Kempe C.H., Bowles C., Meiklejohn G., Berge T.O., Vincent St.L., Babu B.V.S., Govindarajan S., Ratnakannan N.R., Downie A.W., and Murthy V.R. The use of vaccinia hyperimmune gammaglobulin in the prophylaxis of smallpox. Bull. WHO 25 (1961) 41-48
67. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., and Parrott R.H. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89 (1969) 422-434
68. Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine. ARILVAX. Vaccine 22 (2004) 2103-2105
69. Kretzschmar M., Wallinga J., Teunis P., Xing S., and Mikolajczyk R. Frequency of adverse events after vaccination with different vaccinia strains. PLoS Med. (2006) 3
70. Krugman S., Giles J.P., Friedman H., and Stone S. Studies on immunity to measles. J. Pediatr. 66 (1965) 471-488
71. Laassri M., Lottenbach K., Belshe R., Wolff M., Rennels M., Plotkin S., and Chumakov K. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. J. Infect. Dis. 192 (2005) 2092-2098
72. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature 314 (1985) 537-539
73. Lederman H.M., and Winkelstein J.A. X-linked agammaglobulinemia: an analysis of 96 patients. Medicine (Baltimore) 64 (1985) 145-156
74. Lindsey N.P., Schroeder B.A., Miller E.R., Braun M.M., Hinckley A.F., Marano N., Slade B.A., Barnett E.D., Brunette G.W., Horan K., Staples J.E., Kozarsky P.E., and Hayes E.B. Adverse event reports following yellow fever vaccination. Vaccine 26 (2008) 6077-6082
75. Lu S. Human versus HIV: round 2 defeat in AIDS vaccine development. Expert Rev. Vaccines 7 (2008) 151-153
76. Manmohan S. Vaccine Adjuvants and Delivery Systems (2007), Hoboken, N.J.
77. Marennikova S.S. The use of hyperimmune antivaccinia gamma-globulin for the prevention and treatment of smallpox. Bull. World Health Organ. 27 (1962) 325-330
78. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., and Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6 (2000) 207-210
79. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., Defawe O.D., Carter D.K., Hural J., Akondy R., Buchbinder S.P., Robertson M.N., Mehrotra D.V., Self S.G., Corey L., Shiver J.W., and Casimiro D.R. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372 (2008) 1894-1905
80. Meldrum M.L. The historical feud over polio vaccine: how could a killed vaccine contain a natural disease?. West J. Med. 171 (1999) 271-273
81. Melnick J.L., Benyesh-Melnick M., Pena R., and Yow M. Effectiveness of Salk vaccine. Analysis of virologically confirmed cases of paralytic and nonparalytic poliomyelitis. JAMA 175 (1961) 1159-1162
82. Moghaddam A., Olszewska W., Wang B., Tregoning J.S., Helson R., Sattentau Q.J., and Openshaw P.J. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat. Med. 12 (2006) 905-907
83. Monath T.P. Yellow fever vaccine. In: Plotkin S. (Ed). Vaccines (2004), W.B. Saunders, Philadelphia pp. 1095-1176
84. Monath T.P., Cetron M.S., and Teuwen D.E. Yellow fever vaccine. In: Plotkin S.A., Orenstein W.A., and Offit P.A. (Eds). Vaccines (2008), Saunders, Elsevier pp. 1725
85. Monath T.P., McCarthy K., Bedford P., Johnson C.T., Nichols R., Yoksan S., Marchesani R., Knauber M., Wells K.H., Arroyo J., and Guirakhoo F. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 20 (2002) 1004-1018
86. Moore J.P., Klasse P.J., Dolan M.J., and Ahuja S.K. AIDS/HIV. A STEP into darkness or light?. Science 320 (2008) 753-755
87. Murphy B.R., and Walsh E.E. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J. Clin. Microbiol. 26 (1988) 1595-1597
88. Nishimura Y., Igarashi T., Haigwood N., Sadjadpour R., Plishka R.J., Buckler-White A., Shibata R., and Martin M.A. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J. Virol. 76 (2002) 2123-2130
89. Orr N., Klement E., Gillis D., Sela T., Kayouf R., Derazne E., Grotto I., Balicer R., Huerta M., Aviram L., Ambar R., Epstein Y., Heled Y., and Cohen D. Long-term immunity in young adults after a single dose of inactivated Hepatitis A vaccines. Vaccine 24 (2006) 4328-4332
90. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D.L., Kitchener H.C., Castellsague X., de Carvalho N.S., Skinner S.R., Harper D.M., Hedrick J.A., Jaisamrarn U., Limson G.A., Dionne M., Quint W., Spiessens B., Peeters P., Struyf F., Wieting S.L., Lehtinen M.O., and Dubin G. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 (2007) 2161-2170
91. Parren P.W., Marx P.A., Hessell A.J., Luckay A., Harouse J., Cheng-Mayer C., Moore J.P., and Burton D.R. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75 (2001) 8340-8347
92. Pettit A. Rapport sur la valeur immunisante des vaccins employes contre le fievre jaune et la valeur therapeutique du serum antiamaril. Bull. Acad. Med. Paris 105 (1931) 522-526
93. Plotkin S.A. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47 (2008) 401-409
94. Priddy F.H., Brown D., Kublin J., Monahan K., Wright D.P., Lalezari J., Santiago S., Marmor M., Lally M., Novak R.M., Brown S.J., Kulkarni P., Dubey S.A., Kierstead L.S., Casimiro D.R., Mogg R., DiNubile M.J., Shiver J.W., Leavitt R.Y., Robertson M.N., Mehrotra D.V., and Quirk E. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin. Infect. Dis. 46 (2008) 1769-1781
95. Pugachev K.V., Guirakhoo F., and Monath T.P. New developments in flavivirus vaccines with special attention to yellow fever. Curr. Opin. Infect. Dis. 18 (2005) 387-394
96. Putz M.M., Alberini I., Midgley C.M., Manini I., Montomoli E., and Smith G.L. Prevalence of antibodies to Vaccinia virus after smallpox vaccination in Italy. J. Gen. Virol. 86 (2005) 2955-2960
97. Richie E.E., Punjabi N.H., Sidharta Y.Y., Peetosutan K.K., Sukandar M.M., Wasserman S.S., Lesmana M.M., Wangsasaputra F.F., Pandam S.S., Levine M.M., O'Hanley P.P., Cryz S.J., and Simanjuntak C.H. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 18 (2000) 2399-2410
98. Robertson, S., 1993. Poliomyelitis, The Immunological Basis for Immunization Series. Module 6, World Health Organization Global Programme for Vaccines and Immunization, Geneva, Switzerland, pp. 24.
99. Rogers L.J., Eva L.J., and Luesley D.M. Vaccines against cervical cancer. Curr. Opin. Oncol. 20 (2008) 570-574
100. Sanna P.P., and Burton D.R. Role of antibodies in controlling viral disease: lessons from experiments of nature and gene knockouts. J. Virol. 74 (2000) 9813-9817
101. Sawyer L.A. Antibodies for the prevention and treatment of viral diseases. Antiviral Res. 47 (2000) 57-77
102. Sawyer W.A. Persistence of yellow fever immunity. J. Prev. Med. 5 (1931) 413-428
103. Schlesinger J.J., Brandriss M.W., Cropp C.B., and Monath T.P. Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J. Virol. 60 (1986) 1153-1155
104. Sekaly R.P. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?. J. Exp. Med. 205 (2008) 7-12
105. Sencer D., Langmuir A., and Kokko U. Fatal viral encephalitis following 17D yellow fever vaccine inoculation. Report of a case in a 3-year-old child. JAMA 198 (1966) 671-672
106. Shay D.K., Holman R.C., Newman R.D., Liu L.L., Stout J.W., and Anderson L.J. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282 (1999) 1440-1446
107. Siegrist C.-A. Vaccine Immunology. In: Plotkin S.A., Orenstein W.A., and Offit P.A. (Eds). Vaccines (2008), Saunders, Elsevier 1725
108. Skerrett S.J. Antibody treatment of lower respiratory tract infections. Semin. Respir. Infect. 16 (2001) 67-75
109. Skull S., and Kemp A. Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973-93. Arch. Dis. Child 74 (1996) 527-530
110. Slifka M.K. Immunological memory to viral infection. Curr. Opin. Immunol. 16 (2004) 443-450
111. Slifka M.K., and Ahmed R. Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity. Trends Microbiol. 4 (1996) 394-400
112. Slifka M.K., and Hanifin J.M. Smallpox: the basics. Dermatol. Clin. 22 (2004) 263-274 vi
113. Steinbrook R. One step forward, two steps back-will there ever be an AIDS vaccine?. N. Engl. J. Med. 357 (2007) 2653-2655
114. Stephan J.L., Vlekova V., Le Deist F., Blanche S., Donadieu J., De Saint-Basile G., Durandy A., Griscelli C., and Fischer A. Severe combined immunodeficiency: a retrospective single-center study of clinical presentation and outcome in 117 patients. J. Pediatr. 123 (1993) 564-572
115. Stern P.L., Brown M., Stacey S.N., Kitchener H.C., Hampson I., Abdel-Hady E.S., and Moore J.V. Natural HPV immunity and vaccination strategies. J. Clin. Virol. 19 (2000) 57-66
116. Struchiner C.J., Luz P.M., Dourado I., Sato H.K., Aguiar S.G., Ribeiro J.G., Soares R.C., and Codeco C.T. Risk of fatal adverse events associated with 17DD yellow fever vaccine. Epidemiol. Infect. 132 (2004) 939-946
117. Sutter R.W., Kew O.M., and Cochi S.L. Poliovirus vaccine-live. In: Plotkin S.A., Orenstein W.A., and Offit P.A. (Eds). Vaccines (2008), Saunders/Elsevier p. 1725
118. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356 (2007) 1915-1927
119. Turner G.S., Squires E.J., and Murray H.G. Inactivated smallpox vaccine. A comparison of inactivation methods. J. Hyg. (Lond.) 68 (1970) 197-210
120. Ukkonen P., Hovi T., von Bonsdorff C.-H., Saikku P., and Penttinen K. Age-specific prevalence of complement-fixing antibodies to sixteen viral antigens: a computer analysis of 58 500 patients covering a period of eight years. J. Med. Virol. 13 (1984) 131-148
121. Vasconcelos P.F., Luna E.J., Galler R., Silva L.J., Coimbra T.L., Barros V.L., Monath T.P., Rodigues S.G., Laval C., Costa Z.G., Vilela M.F., Santos C.L., Papaiordanou P.M., Alves V.A., Andrade L.D., Sato H.K., Rosa E.S., Froguas G.B., Lacava E., Almeida L.M., Cruz A.C., Rocco I.M., Santos R.T., and Oliva O.F. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 358 (2001) 91-97
122. Wang X.Y., Xu Z., Yao X., Tian M., Zhou L., He L., and Wen Y. Immune responses of anti-HAV in children vaccinated with live attenuated and inactivated hepatitis A vaccines. Vaccine 22 (2004) 1941-1945
123. Wang X.Y., Xu Z.Y., Ma J.C., von Seidlein L., Zhang Y., Hao Z.Y., Han O.P., Zhang Y.L., Tian M.Y., Ouyang P.Y., Zhang Z.Y., Han C.Q., Xing Z.C., and Chen J.C. Long-term immunogenicity after single and booster dose of a live attenuated hepatitis A vaccine: results from 8-year follow-up. Vaccine 25 (2007) 446-449
124. Waris M.E., Tsou C., Erdman D.D., Zaki S.R., and Anderson L.J. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol. 70 (1996) 2852-2860
125. Watkins D.I., Burton D.R., Kallas E.G., Moore J.P., and Koff W.C. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat. Med. 14 (2008) 617-621
126. Wesselhoeft C. Treatment of scarlet fever and diphtheria. Med. Clin. North Am. 19 (1936) 1389-1407
127. Whitton J.L., Slifka M.K., Liu F., Nussbaum A.K., and Whitmire J.K. The regulation and maturation of antiviral immune responses. Adv. Virus Res. 63 (2004) 181-238
128. Zeitlin L., Cone R.A., Moench T.R., and Whaley K.J. Preventing infectious disease with passive immunization. Microbes Infect. 2 (2000) 701-708